Skip to main content

IL-17

      A New ACR
      This is likely an oversimplification, but I've been looking for exactly this diagram

      Inhibiting various TYKs/JAKs corre
      1 month ago
      This is likely an oversimplification, but I've been looking for exactly this diagram Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition @EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No? @rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3
      #0600

      🔬BKZ achieves sustained impact in PsA

      ➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naï
      #0600 🔬BKZ achieves sustained impact in PsA ➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naïve & TNFi-IR PsA pts ➡️Pain,function,fatigue & skin showed greatest & sustained reductions @ 2 yrs👇 🎯BKZ offers sustained response in 🔑PsA domains #ACR24 @RheumNow https://t.co/uhzZoOrr3H
      #0589
      🔬Time to Response in PsA Domains: Secukinumab

      ➡️Post-hoc analyses, n=1366

      🔑Median time (wks) to MCID ?
      #0589 🔬Time to Response in PsA Domains: Secukinumab ➡️Post-hoc analyses, n=1366 🔑Median time (wks) to MCID 👇 🔴Systemic inflammation <2 🔴MSK: ~4 wks (enthesitis~12) 🔴Fatigue~7–8 🔴PASI75~8–12; nails ~24 🩺 Rapid MSK & QoL benefits precede skin/nail #ACR24 @RheumNow https://t.co/WfqkryA1CC
      Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after
      Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr
      #0585 🔬PsA/axSpA: TNFi Cycling v IL-17Ai Switch

      ➡️470 pts: Switchers to IL-17Ai had similar/better outcomes v TN
      #0585 🔬PsA/axSpA: TNFi Cycling v IL-17Ai Switch ➡️470 pts: Switchers to IL-17Ai had similar/better outcomes v TNFi cyclers @ 6 mo ➡️PsA: Switchers had improved arthritis/psoriasis(-5.0, p=0.02) ➡️axSpA: Switchers had improved fatigue(-9.4, p=0.01) #ACR24 @RheumNow
      PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and
      PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe
      With many treatments for #PsA and #PsO, what are the prescribing trends?

      Abstract 0604: TNF inhibitors remain the most
      With many treatments for #PsA and #PsO, what are the prescribing trends? Abstract 0604: TNF inhibitors remain the most common (~60%), but over the past 10 years, IL-17i use rose from 0.2% to 19%, and IL-23i from 0.1% to 39.7%! #ACR24 @RheumNow https://t.co/4TnCAkHfuY
      At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A…
      🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure:
      -Switching to IL1
      🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI
      ×